Stock Events

Stock Events

Arbutus Biopharma 

$4.75
87
+$0.08+1.71% 15:31 Today

Statistics

Day High
4.77
Day Low
4.68
52W High
5.38
52W Low
3.35
Volume
5,519
Avg. Volume
-
Mkt Cap
938.3M
P/E Ratio
5.78
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.13
0.2
0.54
0.87
Expected EPS
-0.0232
Actual EPS
N/A

Financials

-237.88%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
14.08MRevenue
-33.5MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ABUS. It's not an investment recommendation.
Apple
16
AAPL
Microsoft
15
MSFT
Amazon
14
AMZN
Tesla
13
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap25.28B
Moderna is involved in mRNA-based therapies and vaccines, competing in the innovative biopharmaceutical space similar to Arbutus' focus on viral diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, directly competing with Arbutus' RNA-based approaches for treating diseases.
Ionis Pharmaceuticals
IONS
Mkt Cap9.51B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a direct competitor in the RNA space.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap12.24B
Arrowhead Pharmaceuticals is engaged in developing RNAi therapies for a variety of diseases, overlapping with Arbutus' therapeutic areas.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences has a strong presence in antiviral drug development, competing with Arbutus in the hepatitis B virus (HBV) treatment market.
Abbott Laboratories
ABT
Mkt Cap192.51B
Abbott Laboratories offers a broad range of healthcare solutions including diagnostics and treatments for viral infections, competing in the broader healthcare market.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments for infectious diseases, including hepatitis, making it a competitor.
Pfizer
PFE
Mkt Cap152.69B
Pfizer is involved in the development and commercialization of vaccines and antiviral drugs, competing in the infectious disease market.
BioNTech
BNTX
Mkt Cap23.38B
BioNTech SE partners with companies to develop mRNA-based vaccines and therapies, competing in the same innovative space as Arbutus.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals is focused on creating new treatments for viral diseases, including hepatitis C, positioning it as a competitor in the antiviral space.

About

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Show more...
CEO
Lindsay Androski
Employees
19
Country
United States
ISIN
CA03879J1003
WKN
000A14XMD

Listings

STU
DE
I9DN.STU
LSE
GB
0SGC.LSE
MU
DE
I9DN.MU
BOATS
BOATS
ABUS.BOATS

0 Comments

Share your thoughts

FAQ

What is Arbutus Biopharma stock price today?▼
The current price of ABUS is $4.75 USD — it has increased by +1.71% in the past 24 hours. Watch Arbutus Biopharma stock price performance more closely on the chart.
What is Arbutus Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Arbutus Biopharma stocks are traded under the ticker ABUS.
Is Arbutus Biopharma stock price growing?▼
ABUS stock has risen by +4.25% compared to the previous week, the month change is a +4.93% rise, over the last year Arbutus Biopharma has showed a +42.2% increase.
What is Arbutus Biopharma market cap?▼
Today Arbutus Biopharma has the market capitalization of 938.3M
When is the next Arbutus Biopharma earnings date?▼
Arbutus Biopharma is going to release the next earnings report on November 11, 2026.
What were Arbutus Biopharma earnings last quarter?▼
ABUS earnings for the last quarter are -0.03 USD per share, whereas the estimation was -0.02 USD resulting in a -50% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Arbutus Biopharma revenue for the last year?▼
Arbutus Biopharma revenue for the last year amounts to 14.08M USD.
What is Arbutus Biopharma net income for the last year?▼
ABUS net income for the last year is -33.5M USD.
How many employees does Arbutus Biopharma have?▼
As of August 17, 2026, the company has 19 employees.
In which sector is Arbutus Biopharma located?▼
Arbutus Biopharma operates in the Health & Wellness sector.
When did Arbutus Biopharma complete a stock split?▼
Arbutus Biopharma has not had any recent stock splits.
Where is Arbutus Biopharma headquartered?▼
Arbutus Biopharma is headquartered in WARMINSTER, United States.